Closing soon

Metabolomic Analysis of the Effects of Phenylbutyrate (PB) in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Description: The National Heart, Lung, and Blood Institute, on behalf of the National Institutes of Health, issued a Special Notice seeking a non-competitive purchase order to Metabolon, Inc. for untargeted metabolomic profiling and bioinformatic analysis of samples from patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The work covers 75 plasma samples from 30 ME/CFS patients collected before and after eight weeks of sodium phenylbutyrate treatment, plus 15 healthy controls, with three comparative analyses. Capability statements, proposals, or quotations must include specified pricing, delivery, registration, and business information and are due September 8, 2026 at 2:00 p.m. EDT.

Buyer
Released
Sep 1, 2026
Closes
Sep 8, 2026(5 days left)

Files

Original attachments and procurement documents tied to this bid.

Federal RFP files are for Starbridge customers only.

You can request RFP files from all other buyer types for free on this site.

See your top accountsScan your site in seconds. Starbridge identifies your ICP and surfaces emerging opportunities from board meetings, job changes, new grants, contract expirations, RFPs, and more.
See your top 10 accounts